Compare IDEXX Laboratories, Inc. (IDXX) vs iShares Broad USD Investment Grade Corporate Bond (USIG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs iShares Broad USD Investment Grade Corporate Bond — how do they compare? IDEXX Laboratories, Inc. trades at $519.93 (market cap $40.43B), while iShares Broad USD Investment Grade Corporate Bond trades at $48.78 (market cap $17.53B). The key difference: IDEXX Laboratories, Inc. is far larger — about 2.3× iShares Broad USD Investment Grade Corporate Bond's market cap, and IDEXX Laboratories, Inc. is more actively traded (692,164 versus 4,695,583). Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and iShares Broad USD Investment Grade Corporate Bond for 44 Days on average.
| IDXX | USIG | |
|---|---|---|
Market Cap | $40.43B | $17.53B |
Volume | 692,164 | 4,695,583 |
Sector | Health | Fixed Income |
52-Week High | $766.68 | $52.69 |
52-Week Low | $504.70 | $48.54 |
Typical Hold Time | 46 Days | 44 Days |
Enterprise Value | $41.32B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $517.47, up 2.13% with strong earnings momentum after beating Q2 2026 estimates. The stock shows bearish technical signals but maintains robust fundamentals with 25.03% net margins and 74.21% ROE. Recent acquisitions like CoVetAI and expanded diagnostic platforms highlight growth initiatives, while analyst consensus remains bullish with a $665 price target representing 28.5% upside potential.
The outlook remains positive given consistent earnings beats and expanding veterinary diagnostics market share. Key risks include FX headwinds, weaker U.S. vet visits, and premium valuations at 36x P/E. Institutional ownership trends show mixed activity with recent insider selling, but long-term growth drivers in pet healthcare innovation support the bullish analyst stance.
USIG trades at $48.73 with minimal daily movement (+0.1%). Technical indicators show a bearish bias with moving averages signaling caution, though oscillators are neutral. Recent institutional activity includes Blue Edge Capital's new $21.9 million position and Bank of New York Mellon increasing its stake. The company maintains regular dividend distributions, with recent payments of $0.20-$0.21 per share.
The outlook remains cautious given bearish technical signals and limited fundamental data availability. Investment opportunity exists through dividend income and institutional confidence, but risks include market volatility and the need for clearer financial performance metrics to assess valuation properly.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About iShares Broad USD Investment Grade Corporate Bond
USIG is a low-cost ETF providing broad exposure to over 11,000 U.S. investment-grade corporate bonds. It tracks the ICE BofA US Corporate Index, featuring high-quality debt from 2026 leaders like Citigroup, Bank of America, and Oracle.
Read more on USIG →
